Market Cap
$7.1M
SKYE
Skye Bioscience, Inc.
$1.68 ▲ +5.00%
Prev close $1.60Market cap$7.1M
12-mo target$68.00 (+3947.6%)
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SKYE right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
28 funds
Inst. Value
$2.3M
Inst. Activity
2 buys / 3 sells
Insider Activity
$0.00 buy / $889.2K sell
Insider Net $
-$889.2K
SEC Reports
6
Press Releases
3
Price chart 30d -5.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Insider
Schwab Andrew J. sold 114,851 shares
Director @ $1.61 ($184.9K)
Sep 23, 2026 Insider
Schwab Andrew J. sold 4,528 shares
Director @ $1.61 ($7.3K)
Sep 23, 2026 Insider
5AM Partners VII, LLC sold 114,851 shares
10%+ Owner @ $1.61 ($184.9K)
Aug 24, 2026 trading_halt
Aug 20, 2026 SEC Halt Resumed: SKYE — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-21T23:50:00.000Z | Resumed 2026-08-24T13:00:00.000Z
Skye Bioscience filed a DEFA14A to announce the effective date of its previously disclosed 1-for-8 reverse stock split,
DEFA14A — Impact 4/10
Skye Bioscience (SKYE) entered into a definitive transaction agreement to acquire Redx Pharma Limited via a scheme of ar
8-K — Impact 7/10
Skye Bioscience announces a reverse merger with private UK biotech Redx Pharma, forming Fibrx Therapeutics focused on fi
Impact 7/10
Jun 30, 2026 Inst.
UBS Group AG — ADD
73,800 shares ($51.1K)
Analyst ratings buy % -5.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | INITIATE | Buy | 43% |
| Aug 15, 2025 | Evercore ISI Group | INITIATE | Outperform | 59% |
| Jun 24, 2025 | JMP Securities | REITERATE | Market Outperform | 53% |
| Mar 21, 2025 | Craig-Hallum | MAINTAIN | Buy | 54% |
| Mar 21, 2025 | Citizens Capital Markets | REITERATE | Market Outperform | 49% |
| Feb 28, 2025 | William Blair | INITIATE | Outperform | 51% |
| Sep 30, 2024 | Scotiabank | INITIATE | Sector Outperform | 56% |
| Sep 20, 2024 | Piper Sandler | REITERATE | Overweight | 54% |
| Sep 20, 2024 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Sep 10, 2024 | JMP Securities | INITIATE | Market Outperform | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Aug 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Jul 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Jun 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| May 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Apr 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Mar 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% |
Price targets
Where 4 covering analysts think SKYE trades over the next 12 months.
$68.00 +3947.6% upside Strong Buy
Current$1.68 Low$16.00 Median$48.00 High$160.00 4 analysts
$16.00$160.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 2 bearish, 1 mixed, 3 neutral · avg impact 5.0/10.Plus 3 press releases.
NEUTRALDEFA14A4/10
Skye Bioscience filed a DEFA14A to announce the effective date of its previously disclosed 1-for-8 r
Aug 20, 2026
MIXED8-K7/10
Skye Bioscience (SKYE) entered into a definitive transaction agreement to acquire Redx Pharma Limite
Aug 14, 2026
BEARISH8-K7/10
Skye Bioscience received a Nasdaq delisting notice on May 13, 2026, for failing to meet the $10M min
May 15, 2026
BEARISHPRESS-RELEASE7/10
Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net los
May 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 24, 2026
trading_halt
Halt Resumed: SKYE — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-21T23:50:00.000Z | Resumed 2026-08-24T13:00:00.000Z
Aug 21, 2026
trading_halt
Trading Halt: SKYE — T1 (News Pending)
Skye Bioscience, Inc. CS | Market: NASDAQ | Code: T1 — News Pending
Aug 21, 2026
trading_halt
Trading Halt: SKYE — T3 (News and Resumption Times)
Skye Bioscience, Inc. CS | Market: NASDAQ | Code: T3 — News and Resumption Times
Aug 14, 2026
trading_halt
Halt Resumed: SKYE — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-14T14:00:35.000Z | Resumed 2026-08-14T14:05:35.000Z
Aug 14, 2026
trading_halt
Trading Halt: SKYE — LUDP (Volatility Trading Pause)
Skye Bioscience, Inc. CS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.12 | $-1.12–$-1.12 | 56.8% | +44.4% | — | $0.0B | 1 |
| Next Q | $-1.12 | $-1.12–$-1.12 | 62.0% | +38.2% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-5.04 | $-5.04–$-5.04 | 55.6% | +39.8% | — | $0.0B | 1 |
| Next FY | $-7.40 | $-10.80–$-4.56 | -46.8% | +18.3% | 2↑ 0↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.120 | — |
| 7d ago | $-1.120 | — |
| 30d ago | $-2.013 | +0.893 |
| 60d ago | $-2.013 | +0.893 |
| 90d ago | $-2.013 | +0.893 |
Institutional ownership
Which big funds own SKYE (from quarterly 13F filings) and who is adding or trimming.
28 institutional holders with $2.3M total value (3,309,739 shares) as of 2026-Q2. Top holders: ROYAL, BAKER, VANGUARD. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 120 | $0.00 | 0.0% | NEAR_EXIT -93.3% |
| BAKER BROS. ADVISORS LP | 1,575,243 | $1.1M | 47.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 763,882 | $529.4K | 23.1% | — |
| BlackRock, Inc. | 232,874 | $161.5K | 7.0% | TRIM -32.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 218,055 | $151.2K | 6.6% | ADD +31.9% |
| MILLENNIUM MANAGEMENT LLC | 198,524 | $137.6K | 6.0% | TRIM -32.1% |
| VANGUARD FIDUCIARY TRUST CO | 104,229 | $72.2K | 3.1% | — |
| UBS Group AG | 73,800 | $51.1K | 2.2% | ADD +61.3% |
| NORTHERN TRUST CORP | 56,327 | $39.1K | 1.7% | DOUBLED +179.6% |
| Qube Research & Technologies Ltd | 43,082 | $29.9K | 1.3% | TRIM -68.1% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | ADD | 45,762 | 73,800 | +61.3% | $51.1K |
| NORTHERN TRUST CORP | DOUBLED | 20,142 | 56,327 | +179.6% | $39.1K |
| GROUP ONE TRADING LLC | TRIM | 7,205 | 4,589 | -36.3% | $3.2K |
| BARCLAYS PLC | NEAR_EXIT | 18,089 | 655 | -96.4% | $455.00 |
| TD Waterhouse Canada Inc. | TRIM | 79 | 52 | -34.2% | $35.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 210,151 | 277,256 | +31.9% | $170.4K |
| MILLENNIUM MANAGEMENT LLC | TRIM | 380,478 | 258,200 | -32.1% | $158.7K |
| UBS Group AG | DOUBLED | 13,286 | 45,762 | +244.4% | $28.1K |
| GROUP ONE TRADING LLC | TRIM | 17,697 | 7,205 | -59.3% | $4.4K |
| MORGAN STANLEY | TRIM | 4,269 | 2,549 | -40.3% | $1.6K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$889.2K — $0.00 bought, $889.2K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Schwab Andrew J. | Director | SELL | 114,851 | $1.61 | $184.9K |
| Sep 23, 2026 | Schwab Andrew J. | Director | SELL | 4,528 | $1.61 | $7.3K |
| Sep 23, 2026 | 5AM Partners VII, LLC | 10%+ Owner | SELL | 114,851 | $1.61 | $184.9K |
| Sep 23, 2026 | 5AM Partners VII, LLC | 10%+ Owner | SELL | 4,528 | $1.61 | $7.3K |
| Sep 22, 2026 | Schwab Andrew J. | Director | SELL | 27,612 | $1.65 | $45.6K |
| Sep 22, 2026 | Schwab Andrew J. | Director | SELL | 1,088 | $1.65 | $1.8K |
| Sep 22, 2026 | 5AM Partners VII, LLC | 10%+ Owner | SELL | 27,612 | $1.65 | $45.6K |
| Sep 22, 2026 | 5AM Partners VII, LLC | 10%+ Owner | SELL | 1,088 | $1.65 | $1.8K |
| Sep 16, 2026 | 5AM Partners VII, LLC | 10%+ Owner | SELL | 32,607 | $1.91 | $62.3K |
| Sep 16, 2026 | 5AM Partners VII, LLC | 10%+ Owner | SELL | 1,285 | $1.91 | $2.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SKYE.
Shares short
117,086
Settlement Sep 15, 2026
Change vs prior
-9.1%
Semi-monthly cycle
Days to cover
1.4
At avg daily volume
Of shares outstanding
≈2.6%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Aug 21, 2026 | T1 | News Pending | Not resumed |
| Aug 21, 2026 | T3 | Resumption Scheduled | Resumed |
| Aug 14, 2026 | LUDP | Volatility Pause | Resumed |
| Aug 14, 2026 | T1 | News Pending | Not resumed |
| Aug 14, 2026 | T2 | News Released | Not resumed |
All SKYE filing & press-release reports (9)
- DEFA14A reportAug 20, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 12, 2026
- 3 reportApr 29, 2026
- DEFA14A reportApr 16, 2026
- PRESS-RELEASE reportApr 2, 2026
- PRESS-RELEASE reportMar 10, 2026